[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocognitive-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocognitive-function":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,86,118,145,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100388846","phase-2-ucsd-image-guided-cognitive-sparing-radiosurgery-for-brain-metastases-100388846",false,"NCT04343157","UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases","UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions","IG-SRS","Inclusion Criteria:\n\n1. Patients 18 years or older\n2. One to three brain metastases targets, all smaller than 3 cm in diameter (intact or resected tumor bed)\n3. Eastern cooperative Oncology Group (ECOG) performance status 0-2 (score of 0, no symptoms; 1, mild symptoms; 2, symptomatic, \\\u003C50% in bed during the day)\n4. Ability to answer questions and follow commands via neurocognitive testing\n5. Estimated life expectancy greater than 6 months\n6. Pathologic confirmation of extracerebral tumor site (eg, lung, breast, prostate) from either the primary site or a metastatic lesion\n7. Willingness\u002FAbility to undergo brain MRI scans\n8. Able to give informed consent\n\nExclusion Criteria:\n\n1. Pregnant or nursing women\n2. Women of childbearing potential unwilling to use adequate contraception\n3. Inability to complete a magnetic resonance imaging scan with contrast\n4. Tumor directly invading the critical area to be spared (for example a patient with tumor invading a critical white matter tract; ineligible for cognitive-sparing)\n5. Planned chemotherapy during SRS (on the day of SRS)\n6. Previous whole brain radiation therapy\n7. Leptomeningeal metastases (ineligible for SRS)\n8. Metastases from primary germ cell tumor, small cell carcinoma, or primary CNS lymphoma (ineligible for SRS)","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.",[27,28,29],"Brain Metastases, Adult","Neurocognitive Function","Cancer","RECRUITING","2026-06-09",{"date":33,"type":34},"2026-06-10","ACTUAL",{"date":36,"type":34},"2019-05-01",{"date":38,"type":21},"2028-12-31",{"name":40,"class":41},"Jona Hattangadi-Gluth","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":64,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":42},"100376320","impact-of-positive-airway-pressure-therapy-on-clinical-outcomes-in-older-veterans-with-chronic-obstructive-pulmonary-disease-and-comorbid-obstructive-sleep-apnea-overlap-syndrome-100376320","NCT04179981","Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)","Inclusion Criteria:\n\n* OSA with moderate-to-severe disease, AHI 20 per hour by in-lab polysomnography with concomitant moderate-severe COPD based on pulmonary function tests (PFTS) and with past significant history (\\>10 pack-years) of smoking\n* Male or female gender\n* Age greater than or equal to 60 years\n* Stable treatment regimen for COPD\n\nExclusion Criteria:\n\n* Current or prior treatment with PAP or oral appliance\n* Central sleep apnea defined as central apnea index \\>5 per hour and comprising 50% of AHI\n* Known primary neuromuscular diseases\n* Disorders that may impact cognitive function including:\n\n  * neurodegenerative disorders\n  * traumatic brain injury\n* untreated PTSD and\u002For history of learning disability\n* Medicines that may cause or alter sleepiness: sedative hypnotics, or stimulants as these may alter the results\n* Patient is actively suicidal due to depression, unstable mental health condition\n* Epworth sleepiness score \\>16 (severe sleepiness) or a near-miss or prior automobile accident due to sleepiness within the past 12 months\n* Narcolepsy is the primary sleep disorder, with requirement of stimulant medications\n* Employed as a commercial driver or operating heavy machinery\n* On long-term oxygen therapy prior to start of study, more than 12 hr\u002Fday\n* Patients is unable to use either a nasal or face mask (e.g., facial trauma, claustrophobia)\n* Consumption of \\>3 alcoholic beverages per day or current use of some illicit drugs, as these may contribute to cognitive deficits\n* Patients who cannot give informed consent\n* Patients receiving hospice care\n* Pregnant women due to unknown risks","60 Years",{"count":51,"type":21},668,[53],"NA","Obstructive sleep apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD) are highly prevalent chronic respiratory diseases in the Veteran population. OSA co-occurring with COPD, known as Overlap Syndrome (OVS), is a complex chronic medical condition associated with grave consequences. OVS is highly prevalent in Veterans. Veterans with OVS may be at increased risk for cognitive deficits, poor sleep quality as well as a reduced quality of life (QoL). The overall objective is to study the effects of positive airway pressure therapy on clinical outcomes in patients with OVS.",[56,57,58,59,60,28,61,62,63],"Sleep Apnea Syndrome","Obstructive Sleep Apnea","COPD","Overlap Syndrome","Quality of Life","Sleepiness","Elderly","Positive Airway Pressure",[65,66,67,68,69,70,71,72,73,74,75],"Apnea","Sleep Apnea Syndromes","Sleep Apnea, Obstructive","Nervous System Diseases","Respiration Disorders","Respiratory Tract Diseases","Signs and Symptoms, Respiratory","positive airway pressure","cognitive function","quality of life","sleepiness","2026-06-03",{"date":78,"type":34},"2026-06-05",{"date":80,"type":34},"2020-12-01",{"date":82,"type":21},"2027-12-31",{"name":84,"class":85},"VA Office of Research and Development","FED",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100637689","brain-connectivity-changes-in-glioma-patients-during-treatment-100637689","NCT07612917","Brain Connectivity Changes in Glioma Patients During Treatment","Functional Reorganization and Connectivity in Glioma Patients During the Therapeutic Trajectory","GliRecon","Inclusion Criteria:\n\n* Patients with diffuse gliomas (WHO grade 2-4).\n* Age \\>18 years and \\\u003C65 years.\n* Written participant information and informed consent provided and signed.\n* Signed informed consent for functional magnetic resonance imaging (fMRI).\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>65 years.\n* Pregnancy.\n* Contraindications to MRI, including but not limited to:\n\n  * Active medical implants (e.g., pain pump, defibrillator, cardiac pacemaker),\n  * Orthodontic braces,\n  * Metallic tattoos,\n  * Non-removable piercings,\n  * Known metallic foreign bodies,\n  * Claustrophobia.\n* Cerebral metastases from secondary (non-primary) tumors.\n* Absence of baseline BOLD functional MRI and\u002For baseline neurocognitive assessment.\n* Failure to provide written participant information and informed consent.\n* Karnofsky Performance Status (KPS) \\\u003C60, unless feasibility of clinical-psychological testing and BOLD fMRI is confirmed by the investigator in consultation with clinical psychology, radiology staff, and the patient.","64 Years",{"count":96,"type":21},20,"OBSERVATIONAL","The goal of this observational study is to better understand how the brain changes during the treatment of glioma. In particular, the study looks at changes in important brain areas that are responsible for functions such as movement, language, or sensation, as well as the nerve fiber pathways that connect these areas.\n\nThe main question this study aims to answer is:\n\nHow do important brain areas and their connections adapt and reorganize over the course of glioma treatment?\n\nPatients with glioma will undergo repeated brain imaging examinations as part of their regular medical care. These images will be analyzed over time to observe changes in brain activity and structure during different stages of therapy.\n\nBy studying these changes, researchers hope to gain new insights into the brain's ability to adapt (neuroplasticity) throughout the entire course of glioma treatment.",[100,101,102,28],"Glioma (Any Grade) in the Brain","Gliomas, Malignant","fMRI Research",[104,105,106,107,108],"Glioma,","Magnetic Resonance Imaging, Functional","Brain Mapping","Neural Plasticity","Cognition","2026-05-28",{"date":111,"type":34},"2026-05-29",{"date":113,"type":21},"2026-05",{"date":115,"type":21},"2029-12",{"name":117,"class":41},"Johannes Kepler University of Linz",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100565023","phase-2-preventionreduction-of-asrs-and-ptsd-to-sustain-civilian-performance-with-sublingual-cyclobenzaprine-hcl-tnx-102-sl-100565023","NCT06636786","Prevention\u002FReduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)","Prevention\u002FReduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)","OASIS","Inclusion Criteria:\n\n1. ≥ 18 years and ≤ 55 years of age\n2. Presentation to ED within 72 hours of MVC\n3. Anticipated to be discharged home from the ED\n4. Stated willingness to comply with all study procedures and availability for the duration of the study\n5. Consent to receive unencrypted communications\n6. Has a smartphone with continuous service for ≥ 1 year\n7. Has a personal email address they regularly access\n8. Able to speak and read English\n9. Pain severity in the ED ≥ 4 (0-10 numeric rating scale)\n10. People who are not of childbearing potential (e.g., hysterectomy, bilateral oophorectomy, or confirmed postmenopausal for at least last 12 consecutive months)\n11. People with the capacity to conceive a pregnancy must agree to employ a highly effective form of birth control throughout the first 21 days of study participation (e.g., oral, injected, transdermal, or implanted hormonal methods of contraception for at least one full menstrual cycle prior to study drug administration; placement of an intrauterine device (IUD) or intrauterine system (IUS); or double barrier methods such as condoms and diaphragms)\n\nExclusion Criteria:\n\n1. Substantial comorbid injury (e.g., long bone fracture)\n2. People of childbearing potential who are pregnant, breastfeeding, planning to become pregnant, or not using a highly effective form of contraception (e.g., implants, intrauterine devices (IUDs), tubal ligation, hormonal birth control pills, patches, vaginal rings, or injections) during their participation\n3. Prisoner status\n4. Any chronic daily opioid use prior to MVC\n5. Active psychosis, suicidal ideation, or homicidal ideation\n6. Plans for hospital admission\n7. History of arrhythmias, heart block or conduction disturbances, congestive heart failure\n8. Currently in the acute recovery phase of myocardial infarction\n9. Hypersensitivity to cyclobenzaprine or the excipient in TNX-102 SL or placebo formulations\n10. History of urinary retention, angle-closure glaucoma, increased intraocular pressure, or hyperthyroidism (TSH \\\u003C lower limit of normal)\n11. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation due to risk of potential fatal drug-drug interactions\n12. Current or planned use of the following prohibited concomitant medications during study participation: anticholinergic medications, guanethidine, selective serotonin reuptake inhibitors (SSRIs) , serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, MAO inhibitors, anticholinergic medications, guanethidine, potent cytochrome P450 subtype 3A4 inhibitor, St. John's wort, chronic use muscle relaxants or planned use after MCV or other prohibited concomitant medications listed in section 5.6. PI to assess individual cases where single dose of muscle relaxant is prescribed in ED for inclusion\n13. Any hepatic impairment or renal disease (defined as AST OR ALT \\> 3 times the upper limit of normal) or renal disease (defined as GFR ≤ 80 mL\u002Fmin)\n14. Lacking capacity to provide informed consent (receipt of sedative, hypnotic agent making the patient non-decisional for consent)\n15. Any other history or condition that would, in the site investigator's judgement, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g., might interfere with the study, confound interpretation, or endanger patient)\n16. Elevated baseline blood pressure defined as systolic blood pressure ≥ 170 mmHg or diastolic blood pressure ≥ 100 mmHg and or elevated heart rate of ≥115\n17. Abnormal baseline ECG as defined as: QRS duration ≥ 120 ms; QTc \\> 460 ms; not in sinus rhythm; or 1st, 2nd, or 3rd degree heart block indicated\n18. Substance or alcohol use disorder, bipolar disorder, or schizophrenia\n19. History of severe or unexplained oral, or oropharyngeal swelling or edema","55 Years",{"count":128,"type":21},180,[24],"This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a double-blind placebo-controlled randomized clinical trial (RCT) to determine if TNX-102 SL initiated in the ED in the hours after MVC to high risk individuals, treats\u002Freduces acute stress reaction (ASR)\u002Facute stress disorder (ASD) symptoms (primary outcome), improves neurocognitive function, and prevents\u002Freduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 180 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.",[132,133,28,134],"Acute Stress Reaction","Acute Stress Disorder","Post-traumatic Stress","2026-04-09",{"date":137,"type":34},"2026-04-13",{"date":139,"type":34},"2025-03-25",{"date":141,"type":21},"2026-09",{"name":143,"class":41},"University of North Carolina, Chapel Hill",9,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100632711","tavns--cct-for-neurocognitive-rehab-100632711","NCT07517237","taVNS + CCT for Neurocognitive Rehab","Combining At-Home Transcutaneous Auricular Vagus Nerve Stimulation and Computerized Cognitive Training for Neurocognitive Rehabilitation","NeuroHUB","Inclusion Criteria:\n\ni. Ages 45-80 (inclusive) ii. Adequate sensorimotor function (including motor function of dominant hand to complete CCT) and verbal expressive abilities to complete all assessments.\n\niii. Access to reliable Wi-Fi and a Bluetooth-enabled mobile phone or tablet with internet connection capable of supporting study procedures.\n\niv. Self-reported change in cognitive functioning (e.g., memory, attention, thinking abilities) compared to prior functioning, persisting ≥ 6 months and associated with concern and\u002For impact on daily functioning.\n\nv. Is on fixed pharmacotherapy (i.e. stable dose of medication\u002Fs) for ≥ 4 weeks before enrollment, and expected to remain stable throughout study participation. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.\n\nExclusion Criteria:\n\ni. Prior diagnosis of Mild Cognitive Impairment or Dementia (NIA-AA) or Mild or Major Neurocognitive Disorder (DSM-5).\n\nii. taVNS contraindications (e.g., history of seizures, history of trauma or damage to ear, reduced\u002Fimpaired sensation in the ear).\n\niii. MRI contraindications (e.g., ferromagnetic implants, claustrophobia). iv. Presence of a neurological, medical, or psychiatric condition that is acute, unstable, or severe, and that, in the judgment of the study investigators, would significantly interfere with safe participation, valid assessment of cognition or mood, or interpretation of study outcomes.\n\nv. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.\n\nvi. For female participants, a positive pregnancy test if still menstruating within the past 12 months.","45 Years","80 Years",{"count":96,"type":21},[53],"The purpose of this study is to investigate whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with computerized cognitive training might help improve thinking abilities and mood. Participants will self-administer these treatment in their homes and undergo pre- and post-treatment assessments of thinking abilities and mood and brain MRIs.",[159,28,160,161],"Psychosocial Well-being","Cognitive Complaint","Cognitive Dysfunction",[163,161,164,165,166],"Transcutaneous Auricular Vagus Nerve Stimulation","Psychosocial Function","cognitive training","mindfulness meditation","2026-04-03",{"date":169,"type":34},"2026-04-08",{"date":171,"type":34},"2026-03-12",{"date":173,"type":21},"2026-09-15",{"name":175,"class":41},"Medical University of South Carolina",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":183,"sex":17,"minAge":18,"maxAge":184,"enrollmentInfo":185,"targetDuration":186,"studyType":97,"phases":4,"briefSummary":187,"conditions":188,"keywords":194,"overallStatus":198,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100591815","3-dimensional-evaluation-of-body-perception-100591815","NCT06985329","3-Dimensional Evaluation of Body Perception","Evaluation of Neurocognitive Skills, VisuoSpatial Perception and Perspective Perception in Amputees","Inclusion criteria for the amputee group:\n\n* Acquired amputees\n* Aged 18-65 years\n* Using a prosthesis for at least six months\n* At least a primary school graduate\n* Individuals who can adapt to prolonged, attention-demanding activities will be included.\n* Standardised Mini Mental State Examination score of \\>24.\n\nFollowing the recruitment of the amputee group, a healthy control group will be recruited to match it in terms of age, gender and educational status.\n\nInclusion criteria for the healthy control group:\n\n* Age range: 18-65 years\n* At least a primary school graduate\n* Individuals who can adapt to prolonged, attention-demanding activities will be included.\n* Standardised Mini Mental State Examination score of \\>24.\n\nExclusion criteria for the amputee group:\n\n* Individuals with congenital amputation\n* Those with phantom limb pain and\u002For sensation\n* Those with an open wound on the stump\n* Bilateral amputation\n* Any neurological or psychiatric diagnosis\n* Those using sedative medication and\u002For its derivatives\n* Have vision and related problems\n* Individuals who are illiterate\n* Individuals participating in treatments targeting body representation (e.g. imagery-based treatments or progressive motor visualisation) will not be included in the study.\n\nExclusion criteria for the Healthy Control Group:\n\n* Having any neurological or psychiatric diagnosis\n* Using sedative medication and\u002For its derivatives\n* People with vision and related problems\n* Illiterate individuals will not be included in the study.",true,"65 Years",{"count":20,"type":21},"15 Days","The goal of this observational study is to evaluate the changing body perception of amputees aged 18-65 years using prostheses through different personal perspectives of the right-left distinction. In addition, we aimed to examine the relationship between possible changes in body perception and visual spatial perception and neurocognitive performances. The main questions that this study aimed to answer are as follows:\n\n1. Is there a difference between the amputee group and the control group in terms of parameters related to body perception?\n2. Is there a difference between the amputee group and the control group in terms of neurocognitive skills?\n3. Is there any difference between the amputee group and the control group in terms of visual spatial perception abilities?\n\nTo examine whether changes in body perception in amputees affect neurocognitive performance, visuospatial perception and perspective perception and the relationship between them will be compared with a healthy control group.\n\nThe assessments to be applied to both groups can be summarised as follows:\n\n* Demographic information such as age, gender, and education level will be recorded.\n* Mini-mental state test will be used to assess the cognitive level.\n* Edinburgh Handedness Scale will be used to determine the dominant side.\n* Right-left discrimination and personal perspective perception will be assessed using a desktop programme.\n* The clock drawing test and Benton line orientation test will be used to visual spatial perception.\n* A computer based program called The Central Nervous System (CNS) Vital Signs Neurocognitive Test Battery will be used to asesses neurocognitive abilities.",[189,108,190,191,28,192,193],"Body Image","Decision Making","Visuospatial\u002FPerceptual Abilities","Executive Function (Cognition)","Amputation",[189,108,195,193,196,190,197],"Neuropsychological Test","Executive Function","Visuospatial Skills","NOT_YET_RECRUITING","2025-05-14",{"date":201,"type":34},"2025-05-22",{"date":203,"type":21},"2025-06",{"date":205,"type":21},"2026-06-15",{"name":207,"class":41},"Trakya University"]